Global Information
회사소개 | 문의
SALE

비후성 심근증 : 주요 26개국 시장 예측

Epiomic Epidemiology Series: Hypertrophic Cardiomyopathy Forecast in 26 Major Markets 2018-2028

리서치사 Black Swan Analysis
발행일 2018년 08월 상품 코드 339843
페이지 정보 영문 112 Pages
가격
US $ 5,800 US $ 5,104 ₩ 5,800,000 PDF by E-mail (Single User License)
US $ 8,700 US $ 7,656 ₩ 8,700,000 PDF by E-mail (Site License)
US $ 10,400 US $ 9,152 ₩ 10,400,000 PDF by E-mail (Global License)


비후성 심근증 : 주요 26개국 시장 예측 Epiomic Epidemiology Series: Hypertrophic Cardiomyopathy Forecast in 26 Major Markets 2018-2028
발행일 : 2018년 08월 페이지 정보 : 영문 112 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

비후성 심근증(HCM)은 상염색체 우성의 유전 형태를 따르는 질환으로, 유전성이 약간 있습니다. HCM의 주요 특징으로는 좌심실 비대화, 발병 원인을 다른 질환(고혈압, 심부전 등)의 존재로는 설명할 수 없다는 점을 들 수 있습니다.

세계 26개국의 비후성 심근증(HCM: Hypertrophic Cardiomyopathy) 발증 상황을 분석했으며, 질환 개요와 현재 환자수, 성별·연령대별(5세 단락) 상황, 지역별·민족별 동향, 위험인자, 질환의 진단과 예후, 주요 증상과 합병증, 향후 동향 전망(향후 10년간) 등의 정보를 정리하여 전해드립니다.

1. 목차

  • 서론
  • 질환의 원인
  • 위험인자와 예방법
  • 질환의 진단
  • 지역별/민족별 차이
  • 질환의 예후와 임상 경과
  • 질환에 관련된 주요 공존증/특징
  • 환자수 정량화 방법
  • 비후성 심근증(CHM) 최대 환자수
  • HCM 환자의 특징
    • 유전적인 배경
    • 파라미터와 징후
    • HCM의 공존증
  • 약어 리스트
  • 참고 문헌
  • 부록

2. 분석 대상국

  • 미국, 캐나다, 프랑스, 독일, 이탈리아, 스페인, 영국, 폴란드, 네덜란드, 벨기에, 노르웨이, 스웨덴, 덴마크, 오스트리아, 스위스, 아일랜드, 러시아, 터키, 일본, 중국, 한국, 인도, 호주, 브라질, 멕시코, 아르헨티나
LSH 18.08.01

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hypertrophic Cardiomyopathy in 26 Major Markets

Hypertrophic cardiomyopathy (HCM) is a disease that contains an autosomal dominant inheritance pattern and is a moderately common "transmitted" genetic disease. The disease, characterised by hypertrophy in the left ventricle, cannot be explained by the presence of other clinical symptoms, such as hypertension.

This report provides the current prevalent population for HCM across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Austria, Switzerland, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of HCM. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of HCM have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HCM include:

Chronic heart failure

Angina pectoris

Atrial fibrillation

Tachycardia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global HCM market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of HCM and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding on the impact of specific co-morbid conditions on the prevalent population of HCM patients.

Identification of HCM patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of HCM patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR HYPERTROPHIC CARDIOMYOPATHY
  • FEATURES OF HYPERTROPHIC CARDIOMYOPATHY PATIENTS
  • GENETIC BACKGROUND
  • PARAMETERS AND SYMPTOMS
  • COMORBIDITIES OF HYPERTROPHIC CARDIOMYOPATHY PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Prevalence of HCM, total (000s)
  • Table 2. Prevalence of HCM, males (000s)
  • Table 3. Prevalence of HCM, females (000s)
  • Table 4. Patients with HCM by genetic origin, total (000s)
  • Table 5. Patients with familial HCM by gene mutation, total (000s)
  • Table 6. Patients with sporadic HCM by gene mutation, total (000s)
  • Table 7. Familial HCM patients with MYBPC3 mutation by prognosis, total (000s)
  • Table 8. Familial HCM patients with MYH7 mutation by prognosis, total (000s)
  • Table 9. Familial HCM patients with TNNT2 mutation by prognosis, total (000s)
  • Table 10. Familial HCM patients with TNNI3 mutation by prognosis, total (000s)
  • Table 11. Familial HCM patients with MYL2 mutation by prognosis, total (000s)
  • Table 12. Patients with HCM by NYHA class, total (000s)
  • Table 13. Patients with HCM by maximum LV thickness (mm), total (000s)
  • Table 14. Patients with HCM by presence of symptoms, total (000s)
  • Table 15. Symptomatic HCM patients with dyspnoea, total (000s)
  • Table 16. Symptomatic HCM patients with dyspnoea by NYHA class, total (000s)
  • Table 17. Symptomatic HCM patients with clinical heart failure, total (000s)
  • Table 18. Symptomatic HCM patients with angina pectoris, total (000s)
  • Table 19. Symptomatic HCM patients with syncope, total (000s)
  • Table 20. Symptomatic HCM patients with near syncope, total (000s)
  • Table 21. Symptomatic HCM patients with paroxysmal supraventricular tachycardia, total (000s)
  • Table 22. Incidence of HCM-related deaths, total (000s)
  • Table 23. Incidence of HCM-related deaths by cause, total (000s)
  • Table 24. HCM patients with atrial fibrillation, total (000s)
  • Table 25. HCM patients with atrial fibrillation by type, total (000s)
  • Table 26. HCM patients with arterial hypertension, total (000s)
  • Table 27. HCM patients with outflow obstruction, total (000s)
  • Table 28. HCM patients with outflow obstruction by LVOT (mm Hg), total (000s)
  • Table 29. Abbreviations and acronyms used in the report
  • Table 30. USA prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 31. USA prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 32. Canada prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 33. Canada prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 34. France prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 35. France prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 36. Germany prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 37. Germany prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 38. Italy prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 39. Italy prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 40. Spain prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 41. Spain prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 42. UK prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 43. UK prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 44. Poland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 45. Poland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 46. Netherlands prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 47. Netherlands prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 48. Belgium prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 49. Belgium prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 50. Norway prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 51. Norway prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 52. Sweden prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 53. Sweden prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 54. Denmark prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 55. Denmark prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 56. Austria prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 57. Austria prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 58. Switzerland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 59. Switzerland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 60. Ireland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 61. Ireland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 62. Russia prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 63. Russia prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 64. Turkey prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 65. Turkey prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 66. Japan prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 67. Japan prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 68. China prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 69. China prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 70. South Korea prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 71. South Korea prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 72. India prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 73. India prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 74. Australia prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 75. Australia prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 76. Brazil prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 77. Brazil prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 78. Mexico prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 79. Mexico prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
  • Table 80. Argentina prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
  • Table 81. Argentina prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Back to Top
전화 문의
이용안내
 
BCC Research